Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Long-term Debt
Borrowings due after more than one year.
Apogee Therapeutics, Inc.NASDAQ: APGE
Long-term Debt · Q2 FY2026 · quarter ended Jun 2026
Long-term debt remains negative
Q2 FY2026 long-term debt was $0, compared with $0 a year earlier.
Context
- Long-term debt amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Long-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 5.35M USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.35M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Long-term Debt vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
- Long-term debt amounts to 0.0% of total assets for APGE, versus a peer median of 1.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.13B USD | — | — | 87.0% | |
| Jun 2026 | $754.13M USD | +659.6% | +77.4% | 91.1% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥742.8M CNY | -14.5% | -16.3% | 18.7% |
IRONDisc Medicine, Inc. | Sep 2026 | $59.75M USD | +106.4% | — | 8.5% |
| Sep 2026 | $8.11M USD | +170.3% | -22.8% | 0.8% | |
| Mar 2026 | $7.37M USD | -93.3% | -52.3% | 1.1% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Sep 2026 | $0 USD | -100.0% | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding APGE) | — | +45.9% | -19.6% | 1.1% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.